Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients

Next Previous
Search
Trial Profile

A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NEO-PV 01 (Primary) ; Antineoplastics; Pembrolizumab; Temozolomide
  • Indications Giant cell tumours; Glioblastoma; Gliosarcoma; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 24 May 2024 Planned End Date changed from 1 Jan 2026 to 1 Jun 2026.
    • 24 May 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jun 2025.
    • 08 Jun 2021 Results (n=5) assessing assess the immunogenicity, safety and early clinical activity of NEO-PV-01 in combination with pembrolizumab for patients with treatment refractory metastatic solid tumors or or vaccine alone as an adjuvant treatment, presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top